Skip to main content
Important Update Actualización importante:

Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!

¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!

Medicaid Preferred Drug List and Formulary Changes Cambios en el formulario y la lista de medicamentos preferidos de Medicaid

The Vendor Drug Program (VDP) made changes to the Texas Medicaid drug formulary effective July 24, 2026. To learn more about formulary changes impacted, please click here for more information.

El programa de medicamentos de proveedores de Texas (VDP) ha realizado cambios recientes en el formulario de medicamentos de Medicaid de Texas. Esto entrará en vigencia el 24 de julio de 2026. Para obtener más información sobre los cambios en el formulario afectados, visite el siguiente enlace para obtener más información.

Class I Drug Recall Notification: Cyclobenzaprine 10 mg

Date: September 2, 2025

Attention: All Providers

Effective date: August 27, 2025

Call to action: Texas Children’s Health Plan (TCHP) would like inform providers that effective August 27, 2025, Unichem Pharmaceuticals (USA), Inc. voluntarily recalled one (1) lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg to the consumer level. The Cyclobenzaprine 10 mg (90-count) label was inadvertently placed on bottles containing Meloxicam 7.5 mg tablets.

Product affected:

Impacted MedicationNDC No.Lot No.Expiration Date
CYCLOBENZAPRINE HYDROCHLORIDE TABELTS USP 10 MG29300-415-19GMML24026ASept 2027

How this impacts providers: This recall may affect providers whose patients were dispensed the impacted lot, as members may unknowingly be taking Meloxicam instead of Cyclobenzaprine. This could result in ineffective therapy for muscle spasms as well as the potential for adverse effects associated with unintended NSAID use. Providers should be aware that affected patients may contact their offices with questions or concerns and may need counseling regarding discontinuation of the recalled product and appropriate replacement therapy.

Next step for providers: Providers should inform their impacted patients and arrange for the return and replacement of the drug.

If you have any questions, please email TCHP Pharmacy at: providerrelations@texaschildrens.org

For access to all provider alerts,log into:
www.texaschildrenshealthplan.org/provideralerts.